Literature DB >> 11745008

[Opiate addiction in gravidity - consequences for the newborn. Results of an interdisciplinary treatment concept].

K Rohrmeister1, G Bernert, M Langer, G Fischer, M Weninger, A Pollak.   

Abstract

AIMS: To evaluate the outcome of infants of drug dependent mothers (IDM) after establishing an interdisciplinary attention concept at the University Hospital in Vienna. To compare the influence of different maintenance agents on neonatal morbidity. PATIENTS AND METHODS: All newborns of opiate dependent mothers were prospectively included from III 1995 to IX 1999. The following data were collected: maintenance agent (methadone, slow release morphine, buprenorphine), infectious status, demographic data, congenital malformations, perinatal complications, as well as incidence and duration of the neonatal abstinence syndrome (NAS). Medical treatment with phenobarbital (1995 - 96) or morphine hydrochloride (MoHCl) (1997 - 99), respectively, was indicated when Finnegan score exceeded 10.
RESULTS: 88 neonates (38 females/50 males) with a median gestational age of 39 weeks were included, 18 (20.5 %) were born prematurely. The median birthweight was 2905 g, 24 (27.3 %) infants were small for date (< 10th percentile), 15 (17 %) microcephalic. The malformation incidence was 7.4 %. 63 (72 %) of all newborns had to be treated due to abstinence syndrome: in the methadone group 76 %, in the morphine group 93 %, but in the buprenorphine group 19 % only (p < 0.01). Median duration of withdrawal was 15.1 days (d) with significant difference after antenatal buprenorphine exposure compared to methadone and morphine exposure (8.3 d versus 15 d and 16.5 d respectively). In neonates treated with phenobarbital duration of NAS was 17.6 d, whereas NAS in infants with MoHCl therapy lasted 12.8 d (p < 0.05).
CONCLUSION: Incidence and duration of NAS after buprenorphine exposure was significantly lower than after methadone and morphine exposure. Withdrawal time under morphin-hydrochloride therapy was reduced by one third compared to treatment with phenobarbital.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11745008     DOI: 10.1055/s-2001-19054

Source DB:  PubMed          Journal:  Z Geburtshilfe Neonatol        ISSN: 0948-2393            Impact factor:   0.685


  13 in total

1.  Validation and application of a method for the determination of buprenorphine, norbuprenorphine, and their glucuronide conjugates in human meconium.

Authors:  Sherri L Kacinko; Diaa M Shakleya; Marilyn A Huestis
Journal:  Anal Chem       Date:  2007-11-29       Impact factor: 6.986

2.  [Transdermal buprenorphine during pregnancy].

Authors:  E Ebner; M Wiedmann
Journal:  Schmerz       Date:  2006-08       Impact factor: 1.107

3.  Impact of treatment approach on maternal and neonatal outcome in pregnant opioid-maintained women.

Authors:  Verena Metz; Reinhold Jagsch; Nina Ebner; Johanna Würzl; Anna Pribasnig; Constantin Aschauer; Gabriele Fischer
Journal:  Hum Psychopharmacol       Date:  2011-08-08       Impact factor: 1.672

4.  Buprenorphine versus methadone in pregnant opioid-dependent women: a prospective multicenter study.

Authors:  Isabelle Lacroix; Alain Berrebi; Daniel Garipuy; Laurent Schmitt; Yamina Hammou; Catherine Chaumerliac; Maryse Lapeyre-Mestre; Jean-Louis Montastruc; Christine Damase-Michel
Journal:  Eur J Clin Pharmacol       Date:  2011-05-03       Impact factor: 2.953

5.  Should pregnant women with substance use disorders be managed differently?

Authors:  Verena Metz; Birgit Köchl; Gabriele Fischer
Journal:  Neuropsychiatry (London)       Date:  2012-01-25

6.  Correlations of maternal buprenorphine dose, buprenorphine, and metabolite concentrations in meconium with neonatal outcomes.

Authors:  S L Kacinko; H E Jones; R E Johnson; R E Choo; M A Huestis
Journal:  Clin Pharmacol Ther       Date:  2008-08-13       Impact factor: 6.875

Review 7.  Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review.

Authors:  Hendrée E Jones; Sarah H Heil; Andjela Baewert; Amelia M Arria; Karol Kaltenbach; Peter R Martin; Mara G Coyle; Peter Selby; Susan M Stine; Gabriele Fischer
Journal:  Addiction       Date:  2012-11       Impact factor: 6.526

8.  Effect of plasma proteins on buprenorphine transfer across dually perfused placental lobule.

Authors:  Tatiana N Nanovskaya; Robin S Bowen; Svetlana L Patrikeeva; Gary D V Hankins; Mahmoud S Ahmed
Journal:  J Matern Fetal Neonatal Med       Date:  2009-08

9.  [Requirements of a regional medical service for drug addicted patients].

Authors:  Martin Schmidt; Michael V Cranach; Stefan Egger
Journal:  Wien Med Wochenschr       Date:  2006-02

10.  Substance abuse in pregnancy: opioid substitution in a northern Ireland maternity unit.

Authors:  Sandra Mawhinney; Robin G Ashe; Joanne Lowry
Journal:  Ulster Med J       Date:  2006-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.